---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016235"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:58:13.058706+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025

## Summary
- Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.
- Planning Phase 2 trial of ateganosine (THIO) plus checkpoint inhibitor in hepatocellular carcinoma (HCC).
- Expects to begin enrolling HCC trial patients by end of 2025 upon obtaining regulatory approvals.
- FDA granted Orphan Drug Designation for ateganosine in HCC in 2022, potentially 7-year market exclusivity.

## SEC filing metadata
- accession: 0001641172-25-016235
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/0001641172-25-016235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016235
- JSON: https://secwatch.observer/filing/0001641172-25-016235.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.